Together, these findings show that therapeutic depletion of LRRC15+ CAFs from the pancreatic tumour microenvironment leads to markedly improved responsiveness to anti-PDL1 ICB treatment. The gene discussed is LRRC15; the disease is pancreatic neoplasm.